Shots:

• The companies collaborate for the clinical development and commercialization of the ACE-MAB fusion protein that binds to the spike protein of the SARS-CoV-2 virus and treats the COVID-19
• Sorrento will be responsible for the development and commercialization of ACE-MAB in the NA and EU- while Mabpharm retains rights in the ROW- including the China and Japan
• ACE-MAB is a bi-specific fusion protein that consists of two functional arms- with one as Ab targeting the spike protein of SARS-CoV-2 with high affinity and other is a truncated ACE2 protein targeting a different epitope of the spike protein

Click here to­ read full press release/ article | Ref: Sorrento | Image: Contract